36 patents
Page 2 of 2
Utility
Treatment of Skin Conditions Using High Krafft Temperature Anionic Surfactants
4 May 23
The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis.
David W. OSBORNE, David BERK
Filed: 6 May 21
Utility
Compositions and methods for deep dermal drug delivery
18 Apr 23
Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same.
David W. Osborne, Babak N. Tofig
Filed: 16 Nov 21
Utility
Pharmaceutical Compositions of Roflumilast In Aqueous Blends of Water-miscible, Pharmaceutically Acceptable Solvents
23 Mar 23
The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition.
David W. Osborne
Filed: 22 Nov 22
Utility
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
27 Dec 22
The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition.
David W. Osborne
Filed: 22 Sep 17
Utility
Topical Roflumilast Formulation Having Antifungal Properties
9 Jun 22
The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast.
David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
Filed: 3 Dec 21
Utility
Methods for Treating Vitiligo Lesions Having Improved Efficacy
5 May 22
Methods for treating vitiligo lesions including administering to a patient having vitiligo lesions a combination of a topical treatment and ultraviolet B (“UVB”) phototherapy.
Robert HIGHAM, David BERK, Frank WATANABE
Filed: 28 Oct 21
Utility
LAURETH-4 Containing Topical Formulations
3 Feb 22
The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin.
David W. OSBORNE
Filed: 27 Jul 21
Utility
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life
16 Dec 21
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. OSBORNE, Bhaskar CHAUDHURI, Archie W. THURSTON, JR.
Filed: 13 Aug 21
Utility
Topical roflumilast formulation having improved delivery and plasma half life
28 Sep 21
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. Osborne, Bhaskar Chaudhuri, Archie W. Thurston, Jr.
Filed: 31 Jan 20
Utility
Method for Reducing Side Effects from Administration of PHOSPHODIESTERASE-4 Inhibitors
9 Sep 21
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax.
Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
Filed: 21 May 21
Utility
Inhibition of Crystal Growth of Roflumilast
12 Aug 21
Roflumilast crystals have been shown to increase in size during storage.
David W. Osborne
Filed: 23 Nov 20
Utility
Roflumilast Formulations with an Improved Pharmacokinetic Profile
3 Jun 21
An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast.
Howard WELGUS, Archie THURSTON, David W. OSBORNE
Filed: 5 Feb 21
Utility
Inhibition of crystal growth of roflumilast
9 Mar 21
Roflumilast crystals have been shown to increase in size during storage.
David W. Osborne
Filed: 20 Sep 18
Utility
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life
27 May 20
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. OSBORNE, Bhaskar CLAUDHURI, Archie W. THURSTON, Jr.
Filed: 30 Jan 20
Utility
Method for Reducing Side Effects from Administration of PHOSPHODIESTERASE-4 Inhibitors
20 May 20
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax.
Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
Filed: 5 Sep 19
Utility
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
4 Dec 19
Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition.
David W. OSBORNE
Filed: 29 May 19